Litigation Details for Novartis Pharmaceuticals Corporation v. Lupin Atlantis Holdings, S.A. (D. Del. 2020)

Novartis Pharmaceuticals Corporation v. Lupin Atlantis Holdings, S.A. (D. Del. 2020)

Docket		Date Filed	2020-03-24
Court	District Court, D. Delaware	Date Terminated	2022-02-09
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,101,659; 8,404,744; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Lupin Atlantis Holdings, S.A. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-24				External link to document
2020-03-24	12	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,404,744 . (Cottrell, Frederick…2020 9 February 2022 1:20-cv-00415 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-03-24	123	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 8,796,331; 8,877,938…2020 9 February 2022 1:20-cv-00415 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Novartis v. Lupin Atlantis Holdings: Entresto Patent Litigation Summary and Analysis

Last updated: August 8, 2026

Novartis Pharmaceuticals Corporation v. Lupin Atlantis Holdings, S.A., No. 1:20-cv-00415, was a Hatch-Waxman lawsuit in the U.S. District Court for the District of Delaware concerning Lupin’s proposed generic version of Entresto, the sacubitril/valsartan combination product. Novartis asserted multiple Entresto patents after receiving Lupin’s Paragraph IV certification. The case ended without a publicly reported merits judgment, and the commercial terms of the parties’ resolution were not disclosed in the public docket.[1]

The litigation targeted composition, pharmaceutical-combination and related intellectual-property claims covering Entresto tablets. The principal commercial issue was whether Lupin could launch before the expiration of Novartis’ later-expiring Orange Book patents, including patents with listed expiration dates in 2027.[2]

What drug and ANDA were involved in Novartis v. Lupin?

The case involved Entresto, an oral combination of sacubitril and valsartan used for heart failure. Novartis markets Entresto under the application approved by the FDA as NDA 207620. Lupin challenged the listed patents through an abbreviated new drug application, or ANDA, under the Hatch-Waxman Act.[1][3]

Item	Case information
Brand drug	Entresto
Active ingredients	Sacubitril and valsartan
Dosage form	Immediate-release film-coated tablets
NDA holder	Novartis Pharmaceuticals Corporation
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:20-cv-00415
Filing year	2020
Regulatory pathway	ANDA
Challenge type	Paragraph IV patent certification
Defendant	Lupin Atlantis Holdings, S.A.
Litigation result	Publicly docketed resolution without reported merits judgment

Entresto is a small-molecule combination drug. Biosimilar law therefore does not apply. Any competing product would enter through the generic-drug ANDA pathway, not through the abbreviated biologics license application pathway used for biosimilars.

What patents protected Entresto in the Lupin litigation?

Novartis asserted a group of Entresto patents covering the active pharmaceutical combination and related pharmaceutical compositions. The patents most closely associated with the Entresto Paragraph IV litigation include the following:

Patent	General subject matter	Listed expiration information
U.S. Patent No. 8,101,659	Sacubitril/valsartan combination and related therapeutic claims	2023, subject to any applicable pediatric extension
U.S. Patent No. 8,404,744	Pharmaceutical composition and combination-product claims	June 2027
U.S. Patent No. 9,388,134	Sacubitril/valsartan composition claims	June 2027
U.S. Patent No. 9,517,226	Related pharmaceutical-composition claims	June 2027

The exact patent claims and certification positions are controlled by the complaint, Lupin’s ANDA notice letter and the patents listed in the FDA’s Orange Book at the relevant time. Patent listing data can change as products receive supplemental approvals and additional patents are listed.[1][2]

The economic importance of the later-expiring patents was greater than the nominal expiration of the earliest Entresto patent. A generic applicant could avoid one patent through a Paragraph IV position but still face an injunction or settlement tied to other listed patents.

What formulations were protected?

The Entresto estate focused principally on the combination of sacubitril and valsartan in tablet formulations. The relevant intellectual-property barriers included:

• The combination of the two active ingredients.
• Pharmaceutical compositions containing defined amounts or ratios of sacubitril and valsartan.
• Tablet formulations suitable for oral administration.
• Therapeutic use of the combination in heart-failure patients.
• Manufacturing and formulation parameters where claimed by the asserted patents.

Formulation patents can create launch barriers even when a generic applicant does not copy the brand product’s manufacturing process. Under Hatch-Waxman, infringement may arise from the product described in the ANDA, the proposed labeling or both.

When did Lupin challenge Entresto’s patents?

Novartis filed the Delaware action in 2020 after Lupin submitted an ANDA containing Paragraph IV certifications against Entresto patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.[3]

The filing of an infringement action within 45 days of receiving a Paragraph IV notice generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The stay does not automatically determine the patent case. It delays final FDA approval unless the litigation ends earlier, the court issues a decision, or another statutory event occurs.[3]

The core legal issues in this type of action are:

1. Whether Lupin’s proposed sacubitril/valsartan product infringed the asserted claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether Novartis satisfied claim-construction and infringement requirements.
4. Whether any patent was unenforceable because of inequitable conduct or other defenses.
5. Whether a settlement permitted a licensed generic launch before patent expiry.

What was the litigation status and outcome?

The public docket does not show a reported trial verdict or final merits opinion resolving the validity and infringement disputes between Novartis and Lupin. The case was resolved through a docketed termination rather than a publicly reported adjudication of the asserted patent claims.[1]

The public record does not disclose the complete commercial terms of the resolution. As a result, the following matters cannot be treated as established from the docket alone:

• Lupin’s authorized launch date.
• Whether the agreement included a royalty or other payment.
• Whether Lupin received a license covering all listed Entresto patents.
• Whether the agreement included restrictions on formulation, suppliers or manufacturing sites.
• Whether the agreement contained a most-favored-licensee provision.
• Whether the parties agreed to an acceleration clause tied to another generic entrant.

A confidential or partially confidential Hatch-Waxman settlement can end a specific defendant’s case without eliminating the broader patent risk. Other ANDA filers may continue to challenge the same patents in separate litigation.

Did the case involve a Paragraph IV challenge?

Yes. The case was an ANDA patent action based on Lupin’s Paragraph IV certifications. The certification allowed Lupin to challenge the listed Entresto patents before launch rather than waiting for patent expiration.[1][3]

A Paragraph IV filing creates two separate commercial effects:

• It gives the generic applicant a route to challenge the patents and potentially secure an earlier launch.
• It exposes the applicant to infringement litigation and a possible 30-month FDA approval stay.

The certification itself does not invalidate a patent. Novartis retained the burden of proving infringement, while Lupin could attack validity and enforceability through counterclaims and defenses.

What is the Orange Book status of Entresto?

Entresto is an FDA-approved small-molecule product with listed patents in the Orange Book. The Orange Book identifies patents and regulatory exclusivities associated with approved drug products. It does not determine whether a patent is valid or infringed.[2]

The commercial significance of the Entresto listings was the presence of later-expiring patents extending beyond the earliest composition patent. Those listings created potential barriers to an unlicensed generic launch through 2027, subject to patent challenges, court rulings, settlement licenses, regulatory exclusivity and any applicable pediatric extension.

Regulatory or patent event	Commercial effect
NDA approval	Established Entresto’s FDA-approved product and labeling
Orange Book listing	Required ANDA applicants to address listed patents
Paragraph IV certification	Created a pre-launch patent dispute
Novartis infringement suit	Potentially triggered the 30-month stay
Patent settlement	Could establish a negotiated generic entry date
Patent expiration or invalidation	Removed the affected patent barrier
ANDA approval	Permitted approval, but not necessarily lawful commercial launch if other patents remained enforceable

FDA approval and patent clearance are separate questions. An ANDA may be approved while a patent dispute or settlement still controls the date of commercial marketing.

How strong was Novartis’ Entresto patent estate?

The estate was commercially meaningful because it combined an early composition patent with later patents covering the same core product and formulation space. Its strength was reduced by the risk that overlapping claims could face obviousness-type double-patenting, obviousness, written-description and claim-scope challenges.

Strengths

• Entresto has a defined two-active-ingredient product rather than a broad therapeutic category.
• The Orange Book listed multiple patents.
• Later-expiring patents created a potential barrier after expiration of the earliest patent.
• Product-specific claims can be easier to enforce against an ANDA than broad method-of-use claims where the proposed label omits a patented use.
• The product’s commercial success supported a high-value defense and settlement environment, although commercial success alone does not establish nonobviousness.

Weaknesses

• Multiple patents covering closely related subject matter can create double-patenting and obviousness exposure.
• Generic applicants can design around certain formulation limitations.
• A Paragraph IV case creates an early test of validity before generic launch.
• Method-of-use claims may be vulnerable to a “skinny label” strategy if the generic omits the patented indication or dosing instructions.
• A settlement with one applicant does not necessarily bind other ANDA applicants.

The Federal Circuit’s later scrutiny of overlapping pharmaceutical patent claims in related Entresto litigation increased the importance of patent-family structure, terminal disclaimers and the distinction between composition and formulation claims.[4]

What generic launch risks existed for Entresto?

The principal launch scenarios were:

Scenario	Effect on Novartis
Novartis wins on infringement and validity	Lupin’s launch delayed until patent expiry or license
Lupin wins on all asserted patents	FDA approval and commercial launch could proceed, subject to other barriers
Lupin wins on some patents but loses on others	Remaining valid patents could delay launch
Settlement with a negotiated license	Lupin may launch on the agreed date, potentially before the latest patent expiry
At-risk launch	Lupin launches before final resolution and assumes damages and injunction risk
Third-party invalidation	A ruling in another case may weaken the same patent estate for all applicants

The strongest risk to Novartis was not limited to Lupin’s individual product. A favorable judgment for one generic applicant could create persuasive or preclusive effects in later disputes, depending on the judgment and legal posture. A settlement protected Novartis from an immediate adverse merits ruling but left the ultimate market-entry timing dependent on the agreement and other generic challenges.

Which companies challenged or competed with Entresto?

Entresto faced generic competition from ANDA applicants, including Lupin and other manufacturers involved in separate patent disputes or settlement discussions. The relevant competitive set included:

• Large generic manufacturers with ANDA filings.
• Regional generic companies seeking licensed entry.
• Potential authorized-generic strategies.
• Other heart-failure products, including ACE inhibitors, angiotensin receptor blockers and beta-blocker regimens.

The competitive threat was amplified by Entresto’s high sales base. Novartis reported Entresto sales of approximately $6 billion in 2023, making loss of exclusivity a material revenue event.[5]

How did the litigation affect Novartis revenue exposure?

Entresto was one of Novartis’ largest products. A first generic launch would likely affect price, volume and payer substitution. The revenue decline would depend on:

• Number of generic entrants at launch.
• Whether the generic launch was licensed or at risk.
• The number of strengths and dosage forms approved.
• Pharmacy benefit-manager substitution.
• Market share retained by Novartis.
• Authorized-generic arrangements.
• Patent settlements with other ANDA filers.

A single-defendant settlement reduces immediate litigation uncertainty but does not eliminate exposure from later generic entrants. The highest-value question for investors and licensing counterparties is the earliest legally permitted launch date across all ANDA applicants, not the termination date of one case.

What manufacturing and geographic IP barriers remained?

The case concerned U.S. patent rights and FDA-regulated ANDA activity. A Lupin license or dismissal in the United States would not automatically establish freedom to operate in Europe, Canada, Japan or other markets.

Geographic analysis should separate:

• U.S. Orange Book patents.
• Foreign national patent counterparts.
• Regulatory exclusivity in each jurisdiction.
• Manufacturing-site approvals.
• Supplier and active-ingredient restrictions.
• Settlement provisions governing importation, distribution and launch.

For an ANDA product, manufacturing processes, polymorphs, intermediates and suppliers may create additional IP exposure beyond the patents asserted in the Delaware complaint. These barriers are often handled through separate freedom-to-operate reviews and are not fully visible from an infringement complaint.

Key Takeaways

• Novartis v. Lupin Atlantis, No. 1:20-cv-00415, was a Hatch-Waxman Paragraph IV action involving generic sacubitril/valsartan.
• Novartis asserted multiple Entresto-related patents, including U.S. Patent Nos. 8,101,659, 8,404,744, 9,388,134 and 9,517,226.
• The case ended without a publicly reported merits judgment.
• Publicly available docket materials do not disclose the full settlement terms or Lupin’s exact licensed launch date.
• Entresto is a small-molecule combination product, so biosimilar rules do not apply.
• Later-expiring patents listed through 2027 were more commercially important than the earliest Entresto composition patent.
• Entresto’s approximately $6 billion annual sales base created substantial generic-entry exposure for Novartis.
• The case resolution did not necessarily eliminate patent risk from other ANDA applicants.

FAQs About Novartis v. Lupin Atlantis

Was Novartis v. Lupin an Entresto lawsuit?

Yes. The action concerned Lupin’s proposed generic sacubitril/valsartan product, the active combination marketed by Novartis as Entresto.

Did Lupin win the Entresto patent case?

The public docket does not show a merits victory for Lupin. The case ended through a docketed resolution without a reported trial or final validity decision.

Can a generic launch after an Entresto settlement?

Only if the settlement permits launch or the relevant patent barriers no longer apply. FDA approval alone does not establish the right to market the product.

Does Entresto have biosimilar competition?

No. Entresto is a small-molecule drug, not a biologic. Competitive products must generally use the ANDA generic pathway.

What is the most important patent issue in Entresto litigation?

The key issue is whether later-expiring patents covering sacubitril/valsartan compositions and formulations remain valid and enforceable against each ANDA applicant. That question can determine generic launch timing even after the earliest Entresto patent expires.

References

1. U.S. District Court for the District of Delaware. (2020). Novartis Pharmaceuticals Corporation v. Lupin Atlantis Holdings, S.A., No. 1:20-cv-00415. Public docket.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

4. U.S. Court of Appeals for the Federal Circuit. (2024). Novartis Pharmaceuticals Corporation v. MSN Laboratories Private Ltd., related Entresto patent decisions.

5. Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis AG.